Evaluating dengue burden in Africa in passive fever surveillance and seroprevalence studies: protocol of field studies of the Dengue Vaccine Initiative.

Autor:	Lim JK; Global Dengue and Aedes-transmitted Diseases Consortium, International Vaccine Institute, Gwanak-gu, The Republic of Korea.; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK., Carabali M; Global Dengue and Aedes-transmitted Diseases Consortium, International Vaccine Institute, Gwanak-gu, The Republic of Korea.; Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada., Lee JS; Development and Delivery, International Vaccine Institute, Gwanak-gu, The Republic of Korea., Lee KS; Development and Delivery, International Vaccine Institute, Gwanak-gu, The Republic of Korea., Namkung S; Global Dengue and Aedes-transmitted Diseases Consortium, International Vaccine Institute, Gwanak-gu, The Republic of Korea., Lim SK; Global Dengue and Aedes-transmitted Diseases Consortium, International Vaccine Institute, Gwanak-gu, The Republic of Korea., Ridde V; School of Public Health, University of Montreal, Montreal, Quebec, Canada., Fernandes J; Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer, Lambaréné, Gabon., Lell B; Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer, Lambaréné, Gabon., Matendechero SH; Department of Communicable Disease Prevention and Control, Ministry of Health, Nairobi, Kenya., Esen M; Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany., Andia E; Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute, Nairobi, Kenya., Oyembo N; Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute, Nairobi, Kenya., Barro A; Program Equité, Action-Gouvernance-Integration-Reinforcement, Ouagadougou, Burkina Faso., Bonnet E; UMI Résiliences, Institut de recherche pour le developpement (IRD), Paris, France., Njenga SM; Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Kenya Medical Research Institute, Nairobi, Kenya., Agnandji ST; Centre de Recherches Médicales de Lambaréné, Fondation Internationale de l'Hôpital Albert Schweitzer, Lambaréné, Gabon., Yaro S; Centre Muraz, Bobo Dioulasso, Hauts Bassins, Burkina Faso., Alexander N; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK., Yoon IK; Global Dengue and Aedes-transmitted Diseases Consortium, International Vaccine Institute, Gwanak-gu, The Republic of Korea.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2018 Jan 21; Vol. 8 (1), pp. e017673. Date of Electronic Publication: 2018 Jan 21.
DOI:	10.1136/bmjopen-2017-017673
Abstrakt:	Introduction: Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardised methods were launched in three locations in Africa. Methods and Analysis: In 2014-2017, the Dengue Vaccine Initiative initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon and Mombasa, Kenya to obtain comparable incidence data on dengue and assess its burden through standardised hospital-based surveillance and community-based serological methods. Multidisciplinary measurements of the burden of dengue were obtained through field studies that included passive facility-based fever surveillance, cost-of-illness surveys, serological surveys and healthcare utilisation surveys. All three sites conducted case detection using standardised procedures with uniform laboratory assays to diagnose dengue. Healthcare utilisation surveys were conducted to adjust population denominators in incidence calculations for differing healthcare seeking patterns. The fever surveillance data will allow calculation of age-specific incidence rates and comparison of symptomatic presentation between patients with dengue and non-dengue using multivariable logistic regression. Serological surveys assessed changes in immune status of cohorts of approximately 3000 randomly selected residents at each site at 6-month intervals. The age-stratified serosurvey data will allow calculation of seroprevalence and force of infection of dengue. Cost-of-illness evaluations were conducted among patients with acute dengue by Rapid Diagnostic Test. Ethics and Dissemination: By standardising methods to evaluate dengue burden across several sites in Africa, these studies will generate evidence for dengue burden in Africa and data will be disseminated as publication in peer-review journals in 2018. Competing Interests: Competing interests: None declared. (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu